MedTrace Logo

FC Patch Comparator Study

NCT00185354 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 422

Last updated 2015-12-31

No results posted yet for this study

Summary

The purpose of this study is to compare bleeding pattern and safety of contraceptive patch SH P00331F to a marketed comparator.

Conditions

  • Contraception

Interventions

DRUG

BAY86-5016, SH P00331F

Drug amount per patch: 0.9 mg EE2 + 1.9 mg gestodene (GSD)

DRUG

SH P00331N

Drug amount per patch: 0.6 mg EE2 + 6 mg NGM

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-11-30
Primary Completion
2006-04-30
Completion
2006-04-30

Countries

  • Austria
  • Finland
  • France
  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00185354 on ClinicalTrials.gov